Potential Beneficial Role of Nitric Oxide in SARS-CoV-2 Infection: Beyond Spike-Binding Inhibition

Overview

Journal Antioxidants (Basel)

Date 2024 Nov 27

PMID 39594443

Authors

Sergio Sanchez-Garcia

Antonio Castrillo

Lisardo Bosca

Patricia Prieto

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2, the causative virus for the COVID-19 disease, uses its spike glycoprotein to bind to human ACE2 as a first step for viral entry into the cell. For this reason, great efforts have been made to find mechanisms that disrupt this interaction, avoiding the infection. Nitric oxide (NO) is a soluble endogenous gas with known antiviral and immunomodulatory properties. In this study, we aimed to test whether NO could inhibit the binding of the viral spike to ACE2 in human cells and its effects on ACE2 enzymatic activity. Our results show that ACE2 activity was decreased by the NO donors DETA-NONOate and GSNO and by the NO byproduct peroxynitrite. Furthermore, we found that DETA-NONOate could break the spike-ACE2 interaction using the spike from two different variants (Alpha and Gamma) and in two different human cell types. Moreover, the same result was obtained when using NO-producing murine macrophages, while no significant changes were observed in ACE2 expression or distribution within the cell. These results support that it is worth considering NO as a therapeutic agent for COVID-19, as previous reports have suggested.

References

Choi H, Rai P, Chu H, Cool C, Chan E . Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med. 2002; 166(2):178-86. DOI: 10.1164/rccm.2201023. View

Povo-Retana A, Landauro-Vera R, Farinas M, Sanchez-Garcia S, Alvarez-Lucena C, Marin S . Defining the metabolic signatures associated with human macrophage polarisation. Biochem Soc Trans. 2023; 51(4):1429-1436. PMC: 10586766. DOI: 10.1042/BST20220504. View

Silva B, Krogstad P, Teles R, Andrade P, Rajfer J, Ferrini M . IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide. Front Immunol. 2024; 14:1284148. PMC: 10755032. DOI: 10.3389/fimmu.2023.1284148. View

Bastos R, de Lima L, Neto M, Maryam , Yousaf N, Cruz J . Design and Identification of Inhibitors for the Spike-ACE2 Target of SARS-CoV-2. Int J Mol Sci. 2023; 24(10). PMC: 10218936. DOI: 10.3390/ijms24108814. View

Andrabi S, Sharma N, Karan A, Shahriar S, Cordon B, Ma B . Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications. Adv Sci (Weinh). 2023; 10(30):e2303259. PMC: 10602574. DOI: 10.1002/advs.202303259. View

Wolak T, Dicker D, Shifer Y, Grossman A, Rokach A, Shitrit M . A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study. Sci Rep. 2024; 14(1):17201. PMC: 11282178. DOI: 10.1038/s41598-024-68055-w. View

Velkoska E, Dean R, Griggs K, Burchill L, Burrell L . Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond). 2010; 120(8):335-45. PMC: 3018845. DOI: 10.1042/CS20100280. View

Bosca L, Zeini M, Traves P, Hortelano S . Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. Toxicology. 2005; 208(2):249-58. DOI: 10.1016/j.tox.2004.11.035. View

Akerstrom S, Mousavi-Jazi M, Klingstrom J, Leijon M, Lundkvist A, Mirazimi A . Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005; 79(3):1966-9. PMC: 544093. DOI: 10.1128/JVI.79.3.1966-1969.2005. View

10.

Bartesaghi S, Radi R . Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. Redox Biol. 2017; 14:618-625. PMC: 5694970. DOI: 10.1016/j.redox.2017.09.009. View

11.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

12.

Cherian S, Kumar A, Akasapu K, Ashton R, Aparnath M, Malhotra A . Salvage therapies for refractory hypoxemia in ARDS. Respir Med. 2018; 141:150-158. PMC: 6186150. DOI: 10.1016/j.rmed.2018.06.030. View

13.

Crassous P, Couloubaly S, Huang C, Zhou Z, Baskaran P, Kim D . Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol. 2012; 303(5):H597-604. PMC: 3468472. DOI: 10.1152/ajpheart.00138.2012. View

14.

Rico D, Vaquerizas J, Dopazo H, Bosca L . Identification of conserved domains in the promoter regions of nitric oxide synthase 2: implications for the species-specific transcription and evolutionary differences. BMC Genomics. 2007; 8:271. PMC: 1973084. DOI: 10.1186/1471-2164-8-271. View

15.

Shu X, Shi Y, Huang Y, Yu D, Sun B . Transcription tuned by S-nitrosylation underlies a mechanism for Staphylococcus aureus to circumvent vancomycin killing. Nat Commun. 2023; 14(1):2318. PMC: 10120478. DOI: 10.1038/s41467-023-37949-0. View

16.

Winchester S, John S, Jabbar K, John I . Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect. 2021; 83(2):237-279. PMC: 8117664. DOI: 10.1016/j.jinf.2021.05.009. View

17.

Singh S, Wishnok J, Keshive M, Deen W, Tannenbaum S . The chemistry of the S-nitrosoglutathione/glutathione system. Proc Natl Acad Sci U S A. 1996; 93(25):14428-33. PMC: 26149. DOI: 10.1073/pnas.93.25.14428. View

18.

Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K . Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998; 31(1 Pt 2):342-8. DOI: 10.1161/01.hyp.31.1.342. View

19.

Redaelli S, Magliocca A, Malhotra R, Ristagno G, Citerio G, Bellani G . Nitric oxide: Clinical applications in critically ill patients. Nitric Oxide. 2022; 121:20-33. PMC: 10189363. DOI: 10.1016/j.niox.2022.01.007. View

20.

Liu X, Miller M, Joshi M, Sadowska-Krowicka H, Clark D, Lancaster Jr J . Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998; 273(30):18709-13. DOI: 10.1074/jbc.273.30.18709. View